Semisynthetic Glycoconjugate Vaccine Candidates against O25B Induce Functional IgG Antibodies in Mice.

Extraintestinal pathogenic (ExPEC) is a major health concern due to emerging antibiotic resistance. Along with O1A, O2, and O6A, O25B is a major serotype within the ExPEC group, which expresses a unique -antigen. Clinical studies with a glycoconjugate vaccine of the above-mentioned -types revealed O25B as the least immunogenic component, inducing relatively weak IgG titers. To evaluate the immunological properties of semisynthetic glycoconjugate vaccine candidates against O25B, we here report the chemical synthesis of an initial set of five O25B glycan antigens differing in length, from one to three repeat units, and frameshifts of the repeat unit. The oligosaccharide antigens were conjugated to the carrier protein CRM. The resulting semisynthetic glycoconjugates induced functional IgG antibodies in mice with opsonophagocytic activity against O25B. Three of the oligosaccharide-CRM conjugates elicited functional IgGs in the same order of magnitude as a conventional CRM glycoconjugate prepared with native O25B -antigen and therefore represent promising vaccine candidates for further investigation. Binding studies with two monoclonal antibodies (mAbs) revealed nanomolar anti-O25B IgG responses with nanomolar values and with varying binding epitopes. The immunogenicity and mAb binding data now allow for the rational design of additional synthetic antigens for future preclinical studies, with expected further improvements in the functional antibody responses. Moreover, acetylation of a rhamnose residue was shown to be likely dispensable for immunogenicity, as a deacylated antigen was able to elicit strong functional IgG responses. Our findings strongly support the feasibility of a semisynthetic glycoconjugate vaccine against O25B.